2015
Radiation therapy in the locoregional treatment of triple-negative breast cancer
Moran MS. Radiation therapy in the locoregional treatment of triple-negative breast cancer. The Lancet Oncology 2015, 16: e113-e122. PMID: 25752562, DOI: 10.1016/s1470-2045(14)71104-0.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorDecision Support TechniquesDose Fractionation, RadiationFemaleGenetic Predisposition to DiseaseHumansMastectomyNeoplasm Recurrence, LocalPatient SelectionPhenotypePredictive Value of TestsRadiation ToleranceRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTreatment OutcomeTriple Negative Breast Neoplasms
2013
Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?
Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 344-348. PMID: 23910708, DOI: 10.1016/j.ijrobp.2013.05.052.Peer-Reviewed Original ResearchConceptsBreast conservation therapyEarly-stage breast cancer patientsHuman epidermal growth factor receptor 2Recurrence-free survivalBreast cancer patientsKi-67 expressionKi-67Clinicopathologic featuresConservation therapyCancer patientsIndependent associationLocoregional recurrence-free survivalDistant metastasis-free survivalLocal relapse-free survivalEpidermal growth factor receptor 2Univariate/multivariate analysisPrognostic clinicopathologic featuresCause-specific survivalHormone receptor statusGrowth factor receptor 2Metastasis-free survivalRelapse-free survivalKi-67 overexpressionSignificant independent associationKi-67 staining
2010
Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy
Moran MS, Yang Q, Goyal S, Harris L, Chung G, Haffty BG. Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy. International Journal Of Radiation Oncology • Biology • Physics 2010, 81: 1236-1243. PMID: 21093162, DOI: 10.1016/j.ijrobp.2010.07.031.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBlack PeopleBreast NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapyTissue Array AnalysisVascular Endothelial Growth Factor AWhite PeopleConceptsEarly-stage breast cancerBreast-conserving therapyLocal relapse-free survivalRelapse-free survivalVascular endothelial growth factorEarly-stage breast cancer patientsLocal relapseBreast cancer patientsBreast cancerEndothelial growth factorVEGF expressionOverall survivalPrognostic valueCancer patientsTissue microarrayEstrogen receptor/progesterone receptor statusDistant metastasis-free survivalNodal relapse-free survivalGrowth factorProgesterone receptor statusInstitutional review board approvalMetastasis-free survivalLong-term outcomesMargin-negative patientsOverexpression of VEGF
2008
Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy
Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Research And Treatment 2008, 115: 343. PMID: 18516673, DOI: 10.1007/s10549-008-0068-4.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerBreast conservation treatmentStage breast cancerBcl-2 expressionBreast cancerIpsilateral breast tumor recurrenceCox proportional hazards modelBreast tumor recurrenceIndependent prognostic factorProgesterone receptor statusOptimal treatment optionsBcl-2Proportional hazards modelBcl-2 antibodyApoptosis-related proteinsBreast recurrenceLocal relapseLocal recurrencePrognostic factorsReceptor statusClinical outcomesPrognostic significanceTreatment optionsTumor recurrencePrimary tumor